RT Journal Article
SR Electronic
T1 Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.04.20168203
DO 10.1101/2020.08.04.20168203
A1 Shiwani Mahajan
A1 Rajesh Srinivasan
A1 Carrie A. Redlich
A1 Sara K. Huston
A1 Kelly M. Anastasio
A1 Lisa Cashman
A1 Dan Witters
A1 Jenny Marlar
A1 Shu-Xia Li
A1 Zhenqiu Lin
A1 Domonique Hodge
A1 Manas Chattopadhyay
A1 Mark D. Adams
A1 Charles Lee
A1 Lokinendi V. Rao
A1 Chris Stewart
A1 Karthik Kuppusamy
A1 Albert I. Ko
A1 Harlan M. Krumholz
YR 2020
UL http://medrxiv.org/content/early/2020/08/06/2020.08.04.20168203.abstract
AB Importance A seroprevalence study can estimate the percentage of people with SARS-CoV-2 antibodies in the general population. Most existing reports have used a convenience sample, which may bias their estimates.Objective To estimate the seroprevalence of antibodies against SARS-CoV-2 based on a random sample of adults living in Connecticut between March 1 and June 1, 2020.Design Cross-sectional.Setting We sought a representative sample of Connecticut residents who completed a survey between June 4 and June 23, 2020 and underwent serology testing for SARS-CoV-2-specific IgG antibodies between June 10 and July 6, 2020.Participants 505 respondents, aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test.Main outcomes and measures We estimated the seroprevalence of SARS-CoV-2-specific IgG antibodies among the overall population and across pre-specified subgroups. We also assessed the prevalence of symptomatic illness, risk factors for virus exposure, and self-reported adherence to risk mitigation behaviors among this population.Results Of the 505 respondents (mean age 50 [±] years; 54% women; 76% non-Hispanic White individuals) included, 32% reported having at least 1 symptom suggestive of COVID-19 since March 1, 2020. Overall, 18 respondents had SARS-CoV-2-specific antibodies, resulting in the state-level weighted seroprevalence of 3.1 (90% CI 1.4–4.8). Individuals who were asymptomatic had significantly lower seroprevalence (0.6% [90% CI 0.0–1.5]) compared with the overall state estimate, while those who reported having had ≥1 and ≥2 symptoms had a seroprevalence of 8.0% (90% CI 3.1–12.9) and 13.0% (90% CI 3.5–22.5), respectively. All 9 of the respondents who reported previously having a positive coronavirus test were positive for SARS-CoV-2-specific IgG antibodies. Nearly two-third of respondents reported having avoided public places (74%) and small gatherings of family or friends (75%), and 97% reported wearing a mask outside their home, at least part of the time.Conclusions and relevance These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-CoV-2. There is a need for continued adherence to risk mitigation behaviors among Connecticut residents, to prevent resurgence of COVID-19 in this region.Competing Interest StatementDr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the United States Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is a co-founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare artificial intelligence-augmented data management company. Dr. Lee is an Adjunct Professor at The First Affiliated Hospital of Xian Jiaotong University. The other co-authors report no potential competing interests.Funding StatementThis project was supported by the Centers for Disease Control and Prevention through the CARES Act and the Beatrice Kleinberg Neuwirth Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was deemed not to be research by the Institutional Review Board at Yale University because of the public health surveillance activity exclusion and was approved by the Institutional Review Board at Gallup.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A